DENTSPLY SIRONA (NASDAQ:XRAY) Announces FY 2026 Earnings Guidance

DENTSPLY SIRONA (NASDAQ:XRAY) updated its FY 2026 earnings guidance on Thursday. The company provided EPS guidance of 1.200-1.300 for the period, compared to the consensus EPS estimate of 1.470. The company issued revenue guidance of $3.5 billion, compared to the consensus revenue estimate of $3.6 billion.

DENTSPLY SIRONA Price Performance

XRAY opened at $10.09 on Friday. The stock’s 50-day moving average price is $9.63 and its 200 day moving average price is $11.29. DENTSPLY SIRONA has a 12-month low of $8.32 and a 12-month high of $14.76. The firm has a market cap of $2.01 billion, a price-to-earnings ratio of -3.67, a PEG ratio of 1.37 and a beta of 0.87. The company has a current ratio of 1.63, a quick ratio of 1.07 and a debt-to-equity ratio of 1.48.

DENTSPLY SIRONA (NASDAQ:XRAY) last issued its quarterly earnings results on Thursday, November 5th. The medical instruments supplier reported $0.29 earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of $0.31 by ($0.02). DENTSPLY SIRONA had a positive return on equity of 20.84% and a negative net margin of 14.99%. The business had revenue of $836.00 million for the quarter, compared to analysts’ expectations of $861.68 million. During the same quarter last year, the company earned $0.37 earnings per share. The firm’s revenue for the quarter was down 7.5% on a year-over-year basis. DENTSPLY SIRONA has set its FY 2026 guidance at 1.200-1.300 EPS. As a group, sell-side analysts expect that DENTSPLY SIRONA will post 1.39 earnings per share for the current year.

Wall Street Analysts Forecast Growth

Several equities research analysts have weighed in on XRAY shares. Mizuho cut their price target on DENTSPLY SIRONA from $14.00 to $12.00 and set a “neutral” rating on the stock in a report on Thursday, October 22nd. Leerink Partners reduced their price objective on shares of DENTSPLY SIRONA from $14.00 to $10.00 and set a “market perform” rating on the stock in a report on Wednesday, October 14th. Barrington Research lowered their target price on shares of DENTSPLY SIRONA from $15.00 to $13.00 and set an “outperform” rating for the company in a research note on Monday, October 26th. Weiss Ratings reaffirmed a “sell (e+)” rating on shares of DENTSPLY SIRONA in a research report on Friday, October 30th. Finally, Barclays raised their target price on DENTSPLY SIRONA from $9.00 to $11.00 and gave the stock an “underweight” rating in a research report on Monday, August 24th. Three analysts have rated the stock with a Buy rating, eight have issued a Hold rating and three have issued a Sell rating to the stock. According to data from MarketBeat.com, the company currently has an average rating of “Hold” and a consensus price target of $12.58.

Key Stories Impacting DENTSPLY SIRONA

Here are the key news stories impacting DENTSPLY SIRONA this week:

• Positive Sentiment: One report said the company’s third-quarter loss narrowed, a potential bright spot amid otherwise disappointing results. Dentsply Sirona Q3 Loss Narrows
• Negative Sentiment: Adjusted EPS was $0.29, below the $0.31 consensus and down from $0.37 a year earlier. Revenue of $836 million also missed expectations of about $862 million and declined 7.5% year over year. Dentsply Sirona misses Q3 2026 revenue estimates
• Negative Sentiment: XRAY’s 2026 EPS guidance of $1.20–$1.30 and revenue outlook of $3.5 billion came in below analyst expectations of $1.47 and $3.6 billion, respectively, raising concerns about near-term growth and profitability. DENTSPLY SIRONA reports third-quarter results

DENTSPLY SIRONA Company Profile

DENTSPLY SIRONA is a global manufacturer of professional dental products and technologies. The company serves dentists, dental specialists, dental laboratories and other oral health professionals with solutions used in preventive, restorative, prosthetic, endodontic and implant dentistry.

Its portfolio includes dental equipment, imaging and treatment systems, CAD/CAM technology, consumable dental materials, orthodontic products, endodontic instruments and solutions, dental implants, prosthetic components and laboratory products.